Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

part 2 > gynae onc > Flashcards

gynae onc Flashcards

1
Q

AFP raised in

A

Immature teratoma
Sertoli leydig
Yolk sac tumor
Embryonal carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

hcG raised in

A

dysgerminoma
embryonal carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

LDH raised in

A

dysgerminoma
immature teratoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ca125 raised in

A

epithelial tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CEA raised in

A

epithelial tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

estradiol raised in

A

juvenile granulosa cell tumor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

testosterone raised in

A

sertoli-leydig cell tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what tumor markers raised in IMMATURE TERATOMA

A

AFP
LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what tumor markers raised in SERTOLI LEYDIG TUMOR

A

AFP
Testosterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what tumor markers raised in YOLK SAC TUMOR

A

AFP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what tumor markers raised in EMBRYONAL CARCINOMA

A

AFP

hCG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what tumor markers raised in DYSGERMINOMA

A

hCG
LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What tumor markers raised in EPITHELIAL TUMORS

A

CA125

CEA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what tumor markers raised in JGCT?

A

estradiol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

major complication rate for cervical ca

A

27%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

adverse long term bowel QoL effects reported in __% od RT pts?

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

obstruction presents in __% RT for cervical ca

A

14.%%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

fistula present in ___% of women undergoing single or combined treatment for cervical ca

A

8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

radiation cystitis incidence

A

26%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

bladder atony - % requiring ISC

A

2-3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

urinary/vaginal fistula after radical hysterectomy

A

<2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

RT dose that may induce menopause

A

10Gy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

dyspareunia reported in __% after RT for cervical ca

A

55%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

endometrial ca 1y survival overall

A

90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

endometrial ca 5y survival overall

A

75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

endometrial ca 10y survival overall

A

70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

ovarian ca 1y survival overall

A

71%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

ovarian ca 5y survival overall

A

42%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

ovarian ca 10y survival overall

A

35%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

cervical ca 1y survival overall

A

81%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

cervical ca 5y survival overall

A

61%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

cervical ca 10y survival overall

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

vulval ca 1y survival overall

A

86%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

vulva ca 5y survival overall

A

67%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

vaginal ca 1y survival overall

A

90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

vaginal ca 5y survival overall

A

70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

endometrial ca 5y survival by stage

A

92, 74, 47, 15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

ovarian ca 5y survival by stage

A

93, 67, 27, 13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

cervical ca 5y survival by stage

A

87, 67

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

incidence endometrial ca

A

28/100 000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

lifetime risk of endometrial ca

A

3%

10-15% for obese patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

tamoxifen increases risk of endometrial ca by

A

3-6x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

bariatric surgery decreases risk of endometrial ca by

A

70-80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

NPV of ET<4mm on TVS for endo ca

A

> 99%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

positive findings on hysteroscopy, what chance of EC

A

70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

negative findings on hysteroscopy, what chance of EC

A

2.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

failure rate of OPD EB

A

7%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

inadequate sample on EB

A

1% have EC

10% have EH or polyps

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

ovarian cancer incidence

A

9-17/100 000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

lifetime risk of ovarian cancer

A

2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

most important prognostic indicator for ovarian cancer

A

volume of residual disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

staging laparotomy for ovarian cancer

A

1) evaluate peritoneal surfaces
2) washings or retrieve ascites
3) infracolic omentectomy
4) selective lymphadenectomy of pelvic and para-aortic nodes
5) Bx or resection of suspicious lesions
6) random peritoneal Bx
7) TAHBSO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

platinum sensitive ovarian disease

A

relapse >12/12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

platinum partially sensitive ovarian disease

A

relapse 6-12/12

55
Q

platinum resistant ovarian disease

A

relapse <6/12

56
Q

platinum refractory ovarian disease

A

does not respond

use pegylated liposomal doxurubicin, topetocan, or etoposide

57
Q

ovarian staging: disease confined to ovaries or tubes

A

Stage I

58
Q

ovarian staging: one or both ovaries or tubes, pelvic extension, or peritoneal cancer

A

Stage 2

59
Q

ovarian staging: one or both ovaries or tubes, spread to peritoneum outside the pelvis or metastasis to retroperitoneal nodes

A

Stage 3

60
Q

ovarian staging: pleural effusion with positive cytology

A

Stage 4a

61
Q

ovarian staging: parenchymal mets , inguinal nodes, or extra-abdominal organs

A

stage 4b

62
Q

ovarian staging: surgical spill

A

stage IC1

63
Q

ovarian staging: capsule rupture

A

stage 1C2

64
Q

ovarian staging: cells in washings or ascites

A

stage 1C3

65
Q

ovarian staging: extension or implants onto uterus, tubes or ovaries

A

stage 2a

66
Q

ovarian staging: extension to other pelvic intraperitoneal tissues

A

stage 2b

67
Q

ovarian staging: positive retroperitoneal nodes only

A

stage 3a1

68
Q

ovarian staging: peritoneal mets beyond pelvis up to 2cm in diameter

A

stage 3B

69
Q

ovarian staging: peritoneal mets >2cm

A

stage 3C

70
Q

ovarian staging: capsule of liver or spleen

A

stage 3c

71
Q

endometrial staging: <50% myometrial invasion

A

stage 1A

72
Q

endometrial staging: >50% myometrial invasion

A

stage 1B

73
Q

endometrial staging: extension to cervix

A

stage 2

74
Q

endometrial staging: spread to serosa/adnexa

A

stage 3a

75
Q

endometrial staging: spread to vagina or parametrium

A

stage 3b

76
Q

endometrial staging: pelvic nodes

A

stage 3C1

77
Q

endometrial staging: para-aortic nodes

A

stage 3C2

78
Q

endometrial staging: spread to bowel or bladder

A

stage 4a

79
Q

endometrial staging: spread to groin nodes

A

stage 4b

80
Q

cervical ca 1y survival by stage

A

96, 92, 74, 50

81
Q

ovarian ca 1y survival by stage

A

98, 90, 73, 54

82
Q

uterine ca 1y survival by stage

A

99, 95, 83, 46

83
Q

vulval ca 1y survival by stage

A

96, 89, 78, 43

84
Q

lifetime risk of cervical ca

A

1/135

85
Q

HPV type most common in cervical ca

A

16 (and 18, together 75%)

86
Q

age group with highest incidence of cervical ca

A

25-34

25-29 especially?

87
Q

age group with highest incidence of endometrial ca

A

70-74

88
Q

age group with highest incidence of ovarian ca

A

75-79

89
Q

cervical staging: confined to cervix/uterus, <3mm in depth

A

IA1

90
Q

cervical staging: confined to cervix/uterus, 3-5mm in depth

A

IA2

91
Q

cervical staging: confined to cervix, uterus, >5mm in depth and <2cm in dimension

A

IB1

92
Q

cervical staging: confined to cervix/uterus, 2-4cm in dimension

A

IB2

93
Q

cervical staging: confined to cervix/uterus, >4cm in dimension

A

IB3

94
Q

cervical staging: involvement of upper 2/3 vagina, <4cm

A

IIA1

95
Q

cervical staging: involvement of upper 2/3 vagina, >4cm

A

IIA2

96
Q

cervical staging: parametrial involvement

A

IIB

97
Q

cervical staging: lower third of vagina involved

A

IIIA

98
Q

cervical staging: extension to pelvic wall

A

IIIB

99
Q

cervical staging: hydronephrosis

A

IIIB

100
Q

cervical staging: pelvic lymph nodes

A

IIIC1

101
Q

cervical staging: paraaortic lymph nodes

A

IIIC2

102
Q

cervical staging: growth to mucosa of bladder or rectum

A

IVA

103
Q

cervical staging: spread to distant organs

A

IVB

104
Q

cervical ca: management for stage IA1

A

local excision

105
Q

cervical ca: management of stage IA2-2A, <4cm

A

radical hysterectomy and lymphadnectomy

106
Q

cervical ca: management of stage IA1-2A, >4cm

A

chemoradiation

107
Q

cervical ca: management of stage IIB-IVA

A

chemoradiation

108
Q

cervical ca: management of stage IVB

A

combined chemotherapy

109
Q

vulval ca: 5y survival if no nodes involved

A

> 80%

110
Q

vulval ca: 5y survival if inguinal nodes involved

A

<50%

111
Q

vulval ca: 5y survival if iliac or other pelvic nodes involved

A

10-15%

112
Q

vulval staging: confined to vulva, <2cm in size and <1mm deep

A

IA

113
Q

vulval staging: confined to vulva, >2cm in size or >1mm deep

A

IB

114
Q

vulval staging: extension to adjacant perineal structures

A

II

lower third of urethra, lower third of vagina, anus

115
Q

vulval staging: 1 lymph node >5mm

A

IIIA

116
Q

vulval staging: 1-2 lymph nodes <5mm

A

IIIA

117
Q

vulval staging: 2+ lymph nodes >5mm

A

IIIB

118
Q

vulval staging: 3+ lymph nodes <5mm

A

IIIB

119
Q

vulval staging: positive nodes with extracupsular spread

A

IIIC

120
Q

vulval staging: invasion of upper urethra, vaginal mucosa, bladder, rectum

A

IVA

121
Q

vulval staging: fixed or ulcerated inguinofemoral nodes

A

IVA

122
Q

vulval staging: distant mets, including pelvic nodes

A

IVB

123
Q

1 year survival rates range, overall

A

72-89%

worst to best: ovarian, cervical, vulval, endometrial

124
Q

5 year survival rates range, overall

A

42-75%

worst to best: ovarian, cervical, vulval, endometrial

125
Q

going from 1 year to 5 year overall stats, whats the pattern

A

worst = -30,

worst ovarian at 1y becomes best endometrial at 5y

126
Q

1 year - stage 1 survival range across all cancers

A

96-99

127
Q

1 year - stage II survival range across all cancers

A

89-95

-10 from stage 1

128
Q

1 year - stage III survival range across all cancers

A

73-83

-15 from stage 2

129
Q

1 year - stage IV survival range across all cancers

A

43-54

-30 from stage 3

130
Q

5 year - stage 1 survival range across all cancers

A

87-93

*highest = ovarian, lowest = cervical

131
Q

5 year - stage II survival range across all cancers

A

67 and 74

ovarian = cervical

132
Q

5 year - stage III survival range across all cancers

A

27 and 47

ovarian and endometrial only

133
Q

5 year - stage IV survival range across all cancers

A

13 and 15

ovarian and endometrial only

part 2 (21 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions